Align Financial’s Neurocrine Biosciences NBIX Stock Holding History

Align Financial’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$284	Buy	+2	New	+$321	﹤0.01%	589

Other funds holding NBIX

Ninety One (UK) London, United Kingdom $45.5B AUM 15.2% 1-Year Est. Return

PKO BP Bankowy Universal Pension Society Warsaw, Poland $340M AUM 228.33% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

PensionDanmark Copenhagen O, Denmark $12.3B AUM 33.99% 1-Year Est. Return

Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.56B AUM 41.43% 1-Year Est. Return

Align Financial's NBIX Position: Q3 2026 in Review

Align Financial opened a new position in Neurocrine Biosciences (NBIX) in Q3 2026: 2 shares worth $284. The stake represents ﹤0.01% of the portfolio and ranks #589 among its holdings.

109 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.

Align Financial held 2 shares of Neurocrine Biosciences worth $284 as of Q3 2026.
Neurocrine Biosciences was a new Align Financial position in Q3 2026.
Neurocrine Biosciences made up ﹤0.01% of Align Financial's portfolio in Q3 2026, its #589 holding.
109 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.

Based on Align Financial's 13F filing for Q3 2026, filed 16 Oct 2026.